Evidence of efficacy is currently highest for treatment of infantile- and childhood-onset SMA in the early and middle symptomatic phases. While approved indications for nusinersen use in North America and Europe are broad, payer coverage for populations outside those in clinical trials remain variable. Evidence, availability, cost, and patient preferences all influence decision-making regarding nusinersen use.
No takes yet. Share an insight, caveat, or question.
Michelson et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: